Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02115


Purpose:

The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.


Study summary:

- Therapy to prevent GVHD will consist of an infusion of tacrolimus intravenously and sirolimus orally once per day starting 3 days before stem cell infusion. This will take place in the hospital where the patient will remain for the duration of the transplant. - Sirolimus will continue for 9 weeks at at stable dose, then will be tapered by 1/3 on week 9 and 1/3 on week 17. It will be stopped on week 26 if there is no significant evidence of GVHD. These dose modifications will occur at home and patients will be seen weekly for the first 2 months after discharge. - If GVHD is present, the tapering schedule wil be slower and based upon the patient's clinical condition. - Tacrolimus will be given orally once the patient is discharged from the hospital and will be tapered at the same schedule as sirolimus. Blood levels of both tacrolimus and sirolimus will be monitored and the dose adjusted accordingly. - During the year following stem cell transplant, blood work will be performed to evaluate the immune system and GVHD.


Criteria:

Inclusion Criteria: - Patients with hematologic malignancies who will undergo allogeneic HSCT from matched family-members. - Age greater than 18 - ECOG performance status 0-2 - Total bilirubin < 2.0 mg/dl - AST < 90 IU - Serum creatinine < 2.0 mg/dl Exclusion Criteria: - Active, uncontrolled infection - Ejection fraction < 45% by echocardiogram or MUGA scan - Forced vital capacity < 60% - Uncontrolled hypertension - Second transplantation - Evidence of HIV infection - Cholesterol > 300 mg/dl - Relapsed aggressive Burkitt's or Burkitt's-like lymphoma


NCT ID:

NCT00144703


Primary Contact:

Principal Investigator
Corey Cutler, MD, MPH
Dana-Farber Cancer Institute


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02115
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.